Compare Trip.com Group Ltd (TCOM) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Trip.com Group Ltd vs TransMedics Group Inc — how do they compare? Trip.com Group Ltd trades at $43.78 (market cap $28.12B), while TransMedics Group Inc trades at $74.3 (market cap $2.54B). The key difference: Trip.com Group Ltd is far larger — about 11.1× TransMedics Group Inc's market cap, and Trip.com Group Ltd pays a 0.42% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TCOM | TMDX | |
|---|---|---|
Market Cap | $28.12B | $2.54B |
Sector | Consumer Cyclical | Technology |
52-Week High | $78.96 | $150.42 |
52-Week Low | $39.84 | $61.99 |
Enterprise Value | $20.82B | $2.94B |
Dividend Yield | 0.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Trip.com Group (TCOM) trades at $43.65, up 2.83% with strong fundamentals including a 6.64 P/E ratio and 48.65% net margin. Recent Q1 2026 earnings missed expectations at $0.83 per share versus $0.85 expected, though revenue grew 17% year-over-year. Technical indicators show a bullish overall signal with resistance near $45, while news highlights institutional buying and regulatory scrutiny concerns.
The outlook remains positive with a $56.72 analyst price target implying 30% upside, supported by robust cash flow and expanding profitability. Key risks include Q2 revenue guidance of 3%-8% growth lagging expectations and ongoing antitrust investigations in China that could pressure margins near-term.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
